Drug Trial Radar · NCT03192176
A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
Last checked: Nov 20, 2026Latest source record: Nov 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
356
Actual
Start
Jul 19, 2017
Primary completion
Sep 19, 2018
Study completion Sep 19, 2018
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 19, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study determined the effects of different doses and dosing regimens of ESN364 on the frequency and severity of hot flashes. The treatment was administered for 12 weeks to postmenopausal women, aged 40 to 65, suffering at least 50 moderate to severe hot flashes per week.
Conditions
- Menopause
- Hot Flashes
Interventions
FezolinetantDrug
Oral Capsule
PlaceboDrug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Co-Primary Efficacy Endpoint: Change From Baseline (CFB) in The Mean Frequency of Moderate to Severe Vasomotor Symptoms (VMS) at Week 4Time frame: Baseline and week 4
- Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12Time frame: Baseline and week 12
- Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4Time frame: Baseline and week 4
- Co-Primary Efficacy Endpoint: Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12Time frame: Baseline and week 12
Locations
51 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Anniston, Alabama
Research Site
Birmingham, Alabama
Research Site
Phoenix, Arizona
Research Site
Los Angeles, California
Research Site
Oceanside, California
Research Site
Panorama City, California
Research Site 052
Sacramento, California
Research Site 058
Sacramento, California
Research Site
San Diego, California
Research Site
Thousand Oaks, California
Research Site
Valley Village, California
Research Site
Denver, Colorado
Research Site
Milford, Connecticut
Research Site
Crystal River, Florida
Research Site
DeLand, Florida
Research Site
Jupiter, Florida
Research Site
Lake Worth, Florida
Research Site
Miami, Florida
Research Site
Ormond Beach, Florida
Research Site
Port Saint Lucie, Florida
Research Site
Atlanta, Georgia
Research Site
Norcross, Georgia
Research Site
Meridian, Idaho
Research Site
Champaign, Illinois
Research Site
Marrero, Louisiana
Research Site
Elkridge, Maryland
Research Site
Watertown, Massachusetts
Research Site
Lincoln, Nebraska
Research Site
Norfolk, Nebraska
Research Site
Las Vegas, Nevada
Research Site
New York, New York
Research Site
Williamsville, New York
Research Site
Cincinnati, Ohio
Research Site
Cleveland, Ohio
Research Site
Columbus, Ohio
Research Site
Columbus, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Philadelphia, Pennsylvania
Research Site
Mt. Pleasant, South Carolina
Research Site
Clarksville, Tennessee
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.